この記事の翻訳を準備しています。それまでの間、英語の原文を表示します。
ビジネス · 1994/10/141 分で読めます
National Institute of Mental Health; Licensing Opportunity and/or Opportunity for a Cooperative Research and Development Agreement (CRADA) for the Use of Retroviral Vectors With Gibbon Ape Leukemia Virus (GaLV) Components
ローカル自動翻訳 · 情報源の原言語
概要
The National Institutes of Health is seeking licensees and/or CRADA partners for the further development, evaluation, and commercialization of novel retroviral vectors with Gibbon Ape Leukemia Virus (GaLV) components. The invention claimed in the following patent application is available for either exclusive or non-exclusive licensing (in accordance with 35 U.S.C. 207 and 37 CFR Part 404) and/or further development under a CRADA for important clinical and research applications as described below in the Supplementary Information:
情報源の原言語: Federal Register — Health and Human Services原文の発表を開く →